| 注册
首页|期刊导航|中国中药杂志|健脾活骨(康骨)方治疗早期股骨头坏死的中远期临床疗效评价

健脾活骨(康骨)方治疗早期股骨头坏死的中远期临床疗效评价

吴卓耘 周宝强 陈卫衡 宓保宏 李泰贤 王骁汉 王雪惠 林嘉铭 何海军 张彦琼 林娜

中国中药杂志2026,Vol.51Issue(2):316-322,7.
中国中药杂志2026,Vol.51Issue(2):316-322,7.DOI:10.19540/j.cnki.cjcmm.20251020.502

健脾活骨(康骨)方治疗早期股骨头坏死的中远期临床疗效评价

Medium-and long-term clinical efficacy of Jianpi Huogu(Kanggu)Formula in treatment of early-stage femoral head necrosis

吴卓耘 1周宝强 2陈卫衡 3宓保宏 2李泰贤 1王骁汉 2王雪惠 3林嘉铭 1何海军 2张彦琼 3林娜1

作者信息

  • 1. 北京中医药大学 第三附属医院,北京 100029
  • 2. 中医骨伤治疗与运动康复智能化教育部工程研究中心,北京 100029
  • 3. 北京中医药大学 骨伤科研究所,北京 100029
  • 折叠

摘要

Abstract

A long-term follow-up non-randomized controlled study was conducted to evaluate the medium-and long-term efficacy of the Jianpi Huogu(Kanggu)Formula in treating early-stage(ARCO Ⅰ-Ⅱ stage)femoral head necrosis,thereby providing evidence for the early prevention and treatment of the disease with TCM,improvement of symptoms,and delay of disease progression.Patients who received Jianpi Huogu(Kanggu)Formula(experimental group,n=61)or formula combined with TCM infusion therapy(control group,n=168)between January 2003 and June 2020,with a follow-up of≥3 years,were included.Clinical and imaging data at baseline and annual follow-ups were collected,and 40 matched pairs(80 cases)were selected using propensity score matching.The primary endpoints were clinical efficacy(hip pain scores,hip flexion function scores,walking distance scores,and total scores of clinical efficacy)and the Beijing University of Chinese Medicine X-ray Evaluation(BUCMXE),including femoral head morphology scores,osteoarthritis scores,necrotic lesion density scores,and total scores of BUCMXE.The efficacy of the two groups was compared before treatment and at 3,5,and 10 years post-treatment.Clinical efficacy showed that,compared with pre-treatment,both groups had significantly reduced hip pain scores and improved hip flexion function scores,walking distance scores,and total scores of clinical efficacy at 3,5,and 10 years(P<0.001).Imaging evaluation showed that,compared with pre-treatment,femoral head morphology scores in experimental group increased at 3(0.65±1.00,P<0.05),5(0.70±1.02,P<0.001)and 10 years(0.80±1.08,P<0.05);osteoarthritis scores increased at 3(0.32±0.66,P<0.05)and 5 years(0.32±0.67,P<0.05);necrotic lesion density scores decreased at 3(1.18±0.50,P<0.05)and 5 years(1.19±0.52,P<0.05);total scores of BUCMXE increased at 3(2.15±1.29,P<0.05)and 5 years(2.22±1.32,P<0.05).Compared with control group,the femoral head morphology scores increased in experimental group(P<0.05).These results confirm that the Jianpi Huogu(Kanggu)Formula can significantly improve clinical symptoms(pain and joint function)in patients with ARCO Ⅰ-Ⅱ stage femoral head necrosis.Medium-and long-term imaging data suggest slow disease progression(scores not reaching grade Ⅰ pathological criteria).For patients with ARCO Ⅰ stage or mild disease,monotherapy with this formula may be considered.

关键词

早期股骨头坏死/痰瘀阻络证/健脾活骨(康骨)方/中远期疗效

Key words

early-stage femoral head necrosis/phlegm and blood stasis obstructing collateral syndrome/Jianpi Huogu(Kanggu)Formula/medium-and long-term efficacy

引用本文复制引用

吴卓耘,周宝强,陈卫衡,宓保宏,李泰贤,王骁汉,王雪惠,林嘉铭,何海军,张彦琼,林娜..健脾活骨(康骨)方治疗早期股骨头坏死的中远期临床疗效评价[J].中国中药杂志,2026,51(2):316-322,7.

基金项目

国家自然科学基金面上项目(82474548) (82474548)

国家自然科学基金重点项目(82030122) (82030122)

中国中药杂志

1001-5302

访问量3
|
下载量0
段落导航相关论文